Acadian Asset Management LLC Acquires 17,161 Shares of Sierra Oncology Inc (SRRA)

Acadian Asset Management LLC raised its holdings in Sierra Oncology Inc (NASDAQ:SRRA) by 112.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 32,437 shares of the biotechnology company’s stock after acquiring an additional 17,161 shares during the quarter. Acadian Asset Management LLC owned about 0.06% of Sierra Oncology worth $121,000 as of its most recent SEC filing.

SRRA has been the topic of a number of recent research reports. Jefferies Group raised shares of Sierra Oncology from a “hold” rating to a “buy” rating in a research note on Monday, October 23rd. Zacks Investment Research cut shares of Sierra Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $4.00.

Sierra Oncology Inc (SRRA) opened at $2.86 on Friday. Sierra Oncology Inc has a 52 week low of $1.10 and a 52 week high of $4.09. The stock has a market cap of $154.27 and a P/E ratio of -3.01.

Sierra Oncology (NASDAQ:SRRA) last announced its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. equities analysts predict that Sierra Oncology Inc will post -0.85 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Acadian Asset Management LLC Acquires 17,161 Shares of Sierra Oncology Inc (SRRA)” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at

Sierra Oncology Profile

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Want to see what other hedge funds are holding SRRA? Visit to get the latest 13F filings and insider trades for Sierra Oncology Inc (NASDAQ:SRRA).

Institutional Ownership by Quarter for Sierra Oncology (NASDAQ:SRRA)

Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit